4.7 Article

Type I IFN operates pyroptosis and necroptosis during multidrug-resistant A. baumannii infection

期刊

CELL DEATH AND DIFFERENTIATION
卷 25, 期 7, 页码 1304-1318

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41418-017-0041-z

关键词

-

资金

  1. National Key Research and Development Program of China [2017YFD0500300]
  2. Chinese Academy of Sciences [CXJJ-17-M141, Y4ZK111B01, QYZDJ-SSW-SMC012, Y602381081]
  3. National Natural Science Foundation of China [31701134, 81701578]
  4. Chinese Academy Chinese National Natural Science Foundation [21761142002]
  5. Key Laboratory of Bioactive Peptides of Yunnan Province [AMHD-2018-2]

向作者/读者索取更多资源

Multidrug-resistant Acinetobacter baumannii, a common pathogen responsible for nosocomial infections, is the main cause for outbreaks of infectious diseases, such as pneumonia, meningitis, and bacteremia, especially among critically ill patients. Epidemic A. baumannii is a growing public health concern as it is resistant to all existing antimicrobial agents, thereby necessitating the development of new therapeutic approaches to mount an effective immune response against this bacterial pathogen. In this study, we identified a critical role for type I interferon (IFN) in epigenetic regulation during A. baumannii infection and established a central role for it in multiple cell death pathways. A. baumannii infection induced mixed cell death constituted of apoptosis, pyroptosis, and necroptosis. Mechanically, A. baumannii triggered TRIF-dependent type I IFN production, which in turn induced the expression of genes Zbp1, Mlkl, caspase-11, and Gsdmd via KAT2B-mediated and P300-mediated H3K27ac modification, leading to NLRP3 inflammasome activation, and potentially contributed to GSDMD-mediated pyroptosis and MLKL-dependent necroptosis. Our study offers novel insights into the mechanisms of type I IFN and provides potential therapeutic targets for infectious and inflammatory diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据